By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Sex hormone combinations > Estradiol and norethindrone (transdermal) > Estradiol / Norethindrone Dosage
Sex hormone combinations
https://themeditary.com/dosage-information/estradiol-norethindrone-dosage-9169.html

Estradiol / Norethindrone Dosage

Drug Detail:Estradiol and norethindrone (transdermal) (Estradiol and norethindrone (transdermal) [ es-tra-dye-ol-and-nor-eth-in-drone ])

Drug Class: Sex hormone combinations

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Atrophic Urethritis

1 tablet orally once a day

Comments:

  • Use at the lowest effective dose for the shortest duration consistent with treatment goals and risks.
  • Re-evaluate periodically to determine if treatment is still necessary.
  • Only the estradiol 1 mg/norethindrone 0.5 mg strength is recommended for vulvar and vaginal atrophy treatment.

Uses:
  • Treatment of moderate to severe vasomotor symptoms due to menopause
  • Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause
  • Prevention of postmenopausal osteoporosis

Usual Adult Dose for Atrophic Vaginitis

1 tablet orally once a day

Comments:

  • Use at the lowest effective dose for the shortest duration consistent with treatment goals and risks.
  • Re-evaluate periodically to determine if treatment is still necessary.
  • Only the estradiol 1 mg/norethindrone 0.5 mg strength is recommended for vulvar and vaginal atrophy treatment.

Uses:
  • Treatment of moderate to severe vasomotor symptoms due to menopause
  • Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause
  • Prevention of postmenopausal osteoporosis

Usual Adult Dose for Hypoestrogenism

1 tablet orally once a day

Comments:

  • Use at the lowest effective dose for the shortest duration consistent with treatment goals and risks.
  • Re-evaluate periodically to determine if treatment is still necessary.
  • Only the estradiol 1 mg/norethindrone 0.5 mg strength is recommended for vulvar and vaginal atrophy treatment.

Uses:
  • Treatment of moderate to severe vasomotor symptoms due to menopause
  • Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause
  • Prevention of postmenopausal osteoporosis

Usual Adult Dose for Postmenopausal Symptoms

1 tablet orally once a day

Comments:

  • Use at the lowest effective dose for the shortest duration consistent with treatment goals and risks.
  • Re-evaluate periodically to determine if treatment is still necessary.
  • Only the estradiol 1 mg/norethindrone 0.5 mg strength is recommended for vulvar and vaginal atrophy treatment.

Uses:
  • Treatment of moderate to severe vasomotor symptoms due to menopause
  • Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause
  • Prevention of postmenopausal osteoporosis

Usual Adult Dose for Prevention of Osteoporosis

1 tablet orally once a day

Comments:

  • Use at the lowest effective dose for the shortest duration consistent with treatment goals and risks.
  • Re-evaluate periodically to determine if treatment is still necessary.
  • Only the estradiol 1 mg/norethindrone 0.5 mg strength is recommended for vulvar and vaginal atrophy treatment.

Uses:
  • Treatment of moderate to severe vasomotor symptoms due to menopause
  • Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause
  • Prevention of postmenopausal osteoporosis

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Contraindicated

Precautions

US BOXED WARNING(S):
CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER, AND PROBABLE DEMENTIA
Estrogen Plus Progestin Therapy:

  • Cardiovascular Disorders and Probable Dementia
  • Estrogen plus progestin therapy should not be used for prevention of cardiovascular disease or dementia.
  • The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction (MI) in postmenopausal women (50 to 79 years old) taking conjugated estrogens (CE) (0.625 mg) combined with medroxyprogesterone acetate (MPA) (2.5 mg) for 5.6 years, compared to placebo.
  • The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study reported an increase of developing probable dementia in postmenopausal women over 65 years old treated with daily CE (0.625 mg) with MPA (2.5 mg) compared to placebo; it is unknown if this applies to younger postmenopausal women.

  • Breast Cancer
  • The WHI estrogen plus progestin substudy reported an increased risk of invasive breast cancer.
  • Lacking comparable data, assume the risk is similar for other doses of CE and MPA doses, and other combinations and dosage forms of estrogens and progestins.

Estrogen Alone Therapy:
  • Endometrial Cancer
  • Endometrial cancer risk is increased in a woman with a uterus using unopposed estrogens.
  • Adding a progestin to estrogen therapy reduces the risk of endometrial hyperplasia, which may be an endometrial cancer precursor.
  • Perform diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

  • Cardiovascular Disorders and Probable Dementia
  • Estrogen alone therapy should not be used for prevention of cardiovascular disease or dementia.
  • The WHI estrogen-alone ancillary study reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years old) taking daily CE (0.625 mg) for 7.1 years, relative to placebo.
  • The WHIMS estrogen-alone ancillary study reported an increased risk of probable dementia in postmenopausal women over 65 taking daily CE (0.625 mg) for 5.2 years, relative to placebo; it is unknown if this applies to younger postmenopausal women.
  • Lacking comparable data, assume the risk is similar for other doses and dosage forms of estrogens.

Recommendation:
  • Estrogens, with or without progestins, should be prescribed at the lowest effective dose for the shortest duration consistent with treatment goals and risks.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Share this Article
Latest News
Medical News

Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk

Jun 01, 2025
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Heart health: Exercise not enough to offset effects of poor sleep
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by